Arabic Arabic English English French French German German
dark

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Built-In Financial Services Can Help Healthcare Providers Rebound Post-Pandemic

Next Post

Happify Health & Higi Partnership to Create an AI-Driven Patient-Engagement Ecosystem that Makes Value-Based Healthcare Accessible Worldwide

Related Posts
Total
0
Share